Drug Discovery 2012 - ELRIG Innovation Initiative. Chris received a B.S. in Biology from Cornell University

  • View
    0

  • Download
    0

Embed Size (px)

Text of Drug Discovery 2012 - ELRIG Innovation Initiative. Chris received a B.S. in Biology from Cornell...

  • www.elrig.org

    Drug Discovery 2012 Manchester Central Convention Complex, UK

    5th & 6th September 2012

    In collaboration with

  • Welcome Words Welcome to the sixth Drug Discovery meeting organized by ELRIG (European Laboratory Robotics Interest Group) in collaboration with SLAS (Society for Laboratory Automation and Screening).

    Proposals for the annual ELRIG Drug Discovery meeting were developed during 2005 and 2006 and led to the first meeting being held in Nottingham in 2007. Since that time we have had the privilege of acting as program chairs for six annual meetings. We have seen the meeting double in size, have established the leading vendor exhibition in the UK and have welcomed many eminent scientists including Jamie Thomson, Chris Lipinski and Philip Cohen to the meeting. More importantly, the Drug Discovery meeting has become established within the meetings calendar as the major meeting place in the UK for scientists from pharma, biotech and academia interested in the challenges of pre-candidate drug discovery.

    We would now like to welcome delegates, exhibitors and speakers to the sixth annual meeting to be held once again at the Manchester Central exhibition centre. This meeting marks our final year as program chairs. Over the next two days a superb range of world-class Speakers will be presenting in eight sessions covering a wide range of topical issues for Drug Discovery including advances in Fragment Based Drug Discovery and the complimentary biophysical and label free technologies applied in this field. We will explore the biology of epigenetic enzymes and ubiquitinases as two novel families of drug targets. We will once again discuss advances in assay development and screening, compound management and compound collection enhancement, liquid handling and detection technologies. Building on the success of previous years we will review the application of primary and stem cells in discovery. In addition, the 2012 meeting will contain two lunchtime sessions in collaboration with SLAS to explore the growing informatics challenge of extracting knowledge from laboratory data.

    The meeting features an extensive array of posters, snapshot talks, training, several competitions and probably the best exhibition for Drug Discovery products and services in the UK which incorporates a thriving Innovation Zone for new companies promoting exciting technologies to the market. We also add to our conference program what we hope will be a challenging and entertaining Dragon’s Den event in which innovators will present new ideas to a panel of industry leaders for discussion. Finally there will be a range of exhibitor organised meetings and training courses.

    The meeting will end with a debate on the Evolving Landscape of Drug Discovery hosted by Chris Moxham who will discuss the Lilly model of Open Innovation and Steve Rees from AstraZeneca who will discuss Collaborative models for Lead Discovery.

    In developing the program for this meeting ELRIG is placed at the centre of our community with the objective of bringing together scientists from across the field, whether they are based in academia, the pharmaceutical or biotech industries, in order to establish relationships to advance the science of drug discovery in the UK and Europe.

    As in past years registration and attendance at the show is FREE – we can only do this because of the support of our sponsors and exhibitors.

    As we now pass the baton to Del Trezise (Essen) and Peter Simpson (AstraZeneca) the Program Chairs for the 2013 show, we would like to thank everyone who has contributed to six years of the Drug Discovery event but, especially Jackie Howard and Dermot Boylan of ELRIG without whom these meetings simply would not happen.

    Drug Discovery 2013 will be back in Manchester on 3rd & 4th September 2013 so please make a date in your diary!

    With best regards,

    Adrian Kinkaid and Stephen Rees Program Chairs Drug Discovery 2012

    About ELRIG ELRIG is a Not For Profit special interest group focused on the use of automation, robotics and instrumentation in the laboratory and also on the wider applications of laboratory automation.

    Our membership consists of scientists, researchers, engineers, developers and business-people who are interested in robotics, automation and associated technological developments in this field.

    Our primary objective is to provide an open communication forum for users and vendors, within which members can be educated, share information and experience and network with other members.

    Our primary means of achieving this is to organise Meetings and Conferences in which our members' experiences of automation are presented and at which relevant vendors exhibit their latest technology. Our aim is to provide world-class meetings and conferences which are accessible to all.

    In order to meet our open-access aims, we operate a business model in which delegate access to our meetings is Free of Charge. We aim to cover the cost of staging our events from the contributions of the exhibitors and sponsors.

    About SLAS The Society for Laboratory Automation and Screening (SLAS) is an international community of more than 10,000 individual scientists, engineers, researchers, technologists and others from academic, government and commercial laboratories. SLAS provides forums for education and information exchange to encourage the study of and advance laboratory science and technology for the drug discovery, agrochemical, biotechnology, chemical, clinical diagnostic, consumer product, energy, food, forensic, pharmaceutical, security and other industries.

    SLAS works hard to deliver tangible educational programs and services to its members. Professionals at all levels who actively invest their time and energy in their SLAS memberships often experience immeasurable returns on their investments. Those who contribute as volunteers and committee members enjoy even greater advantages.

    Scientific education, practical information, professional career- building, and valuable networking opportunities can open many doors to personal and professional success. Acknowledge your role in the unique field of laboratory science and technology. Join the only international, non-profit society devoted exclusively to your best interests. Join SLAS today at SLAS.org.

    This meeting continues to be the ideal forum for users of Flow Cytometry & Imaging Systems within drug discovery and drug development to get together, share expertise and innovation, discuss pitfalls, successes and future directions. Typical attendees will be colleagues from small-to mid-sized biotech companies, contract research organisations and global pharmaceutical companies. The content of this free two day meeting will also include other industrial-based themes covering the drug development journey from discovery to clinical evaluation.

  • Chris Moxham Chris is currently an Associate Vice President at ImClone Systems, a wholly owned subsidiary of Eli Lilly and Company. Prior to joining ImClone, he spent 12 years at Eli Lilly and Co. in a variety of leadership roles. Most

    recently he led a team that developed and launched Eli Lilly’s Open Innovation Initiative. Chris received a B.S. in Biology from Cornell University and a Ph.D in Molecular and Cellular Pharmacology from the State University of New York at Stony Brook.

    Don’t Miss the Keynote Debate:

    Charter 1 at 3.45 on Day 2

    The Evolving Landscape of Drug Discovery Lilly Model of Open Innovation by Chris Moxham, Lilly

    Collaborative Models for Lead Discovery by Steve Rees, AstraZeneca

    Poster Awards

    Keynote Speakers

    ELRIG Presents The SLAS Young Scientist Award

    Students, graduates and post-docs are welcome to compete for the SLAS Young Scientist Award at the ELRIG Drug Discovery 2012 Annual Conference and Exhibition, September 5-6, at Manchester Central, United Kingdom.

    Students, graduates and post-docs are welcome to compete for the SLAS Young Scientist Award at the ELRIG Drug Discovery 2012 Annual Conference and Exhibition, September 5-6, at Manchester Central, United Kingdom.

    The winner will be invited to present and participate in the Student Poster Competition at the 2nd Annual SLAS Conference and Exhibition, January 12-16, 2013 at the Gaylord Palms Resort and Convention Center in Orlando, Florida, USA. SLAS Young Scientist Award winners receive a $500 cash prize, round-trip coach airfare, shared hotel accommodations and conference registration for SLAS2013.

    The winner will be invited to present and participate in the Student Poster Competition at the 2nd Annual SLAS Conference and Exhibition, January 12-16, 2013 at the Gaylord Palms Resort and Convention Center in Orlando, Florida, USA. SLAS Young Scientist Award winners receive

    a $500 cash prize, roundtrip coach airfare, shared hotel accommodations and conference registration for SLAS2013.

    The SLAS Young Scientist Award program is a global initiative in partnership with the following organizations: • European Laboratory Robotics Interest Group, United Kingdom • Institute of Food Technologists, United States • MipTec, Switzerland • International Society for Stem Cell Research, United States

    For information regarding the ELRIG Drug Discovery 2012 SLAS Young Scientist Award, please contact Dermot Boylan, ELRIG Executive Director, at Dermot.boylan@elrig.org.

    Steve Rees Steve Rees is Vice-President of Screening Sciences and Sample Management at AstraZeneca with global responsibility for High Throughput Screening, Compound Management, the human tissue BioBank and the provision of SAR biology support to preclinical disco